Laughter was bad for Jenna Flaherty. That’s the point she had reached in her lifelong battle against cystic fibrosis, a genetic condition that causes lung infections and makes it hard to breathe.

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

The results represent a "historic" moment in cystic fibrosis care. Vertex has announced successful results from two Phase III studies of Trikafta (elexacaftor ...

The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the ...

And while this was all true for Christchurch youngster Noah Harrington-Ashton, his recent celebrations also marked the ...

Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian ...

Courtney Boccio wasn’t sure what to expect when she started a clinical trial for a new drug aimed at helping people with cystic fibrosis in the spring of 2018. The 25-year-old Huntington woman was ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...